Lonza's expertise and technology is hoped to accelerates timelines while mitigating risks of the development and manufacturing of molecules
Bioqube Ventures, a European venture capital firm, and Lonza, a global CDMO for the pharma and biotech industries, have announced a framework agreement covering a strategic collaboration for the development and manufacturing of biologics and small molecules.
The agreement was developed to support the needs of the VC and its portfolio companies looking to simplify the development of their molecules. Under the terms of the agreement, Lonza will support the company during the due diligence of candidate biotechs and provide tailored advice and services to its portfolio companies.
Debora Dumont, co-founder and Managing Partner, Bioqube Ventures, said: “Bioqube is dedicated to advancing exciting science in the vibrant European ecosystems with the aim of developing breakthrough therapies for patients. This collaboration offers our portfolio companies the opportunity to leverage Lonza's expertise and its global network, supporting our hands-on approach in building new and successful ventures.”
Lonza's expertise and technology is hoped to accelerates timelines while mitigating risks of the development and manufacturing of molecules ranging from monoclonal antibodies, complex proteins, and small molecules to antibody-drug conjugates.
Pnina Weitz, Global Head of Venture Capital Business Development & Relationship Management, Lonza, added: “This framework agreement provides Bioqube Ventures and its portfolio companies a range of services for its late discovery and early development needs. The cornerstone of our ability to successfully accelerate development programs and commercialise products is our proven track record, comprehensive resources and the global network that we bring to our customer's portfolio companies.”